化疗免疫治疗后PET/CT与SPET/CT显示腋窝皮肤成纤维细胞活化蛋白摄取:巧合还是因果关系
本病例系列首次报告33例经化疗和/或免疫治疗后进展的实体瘤患者,在肽靶向放射性核素治疗前的PET/CT与SPET/CT上出现腋窝皮肤弥漫性成纤维细胞活化蛋白(FAP)摄取。体格检查腋窝区未见明显异常。作者推测成纤维细胞活化可能与全身治疗后继发的汗腺受累有关,但腋窝部位好发的原因尚不清楚。
要点
- 33例晚期实体瘤患者PET/CT与SPET/CT显示腋窝皮肤弥漫性FAP摄取。
- 体格检查腋窝区未见明显异常发现。
- 作者推测FAP摄取可能与全身治疗后继发汗腺成纤维细胞活化有关。
核心结论
- 作者提出假说:成纤维细胞活化可能继发于全身治疗而累及汗腺,但腋窝部位好发的原因尚不清楚。
研究设计与样本
- 病例系列,纳入33例经既往化疗和/或免疫治疗后失败、转诊行肽靶向放射性核素治疗的进展性实体瘤患者,行PET/CT与SPET/CT检查。
主要发现
- 33例患者的PET/CT与SPET/CT上观察到腋窝皮肤弥漫性FAP摄取。
- 体格检查腋窝区未见明显异常发现。
临床怎么用
- 作者指出该征象在此临床情境中常见,需要对该征象进行正确解读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) uptake can occur in benign conditions in addition to malignancies. This case series presents the first evidence of diffuse FAP uptake in axillary skin on PET/CT and SPET/CT of 33 patients with progressive solid tumors, referred to peptide-targeted radionuclide therapy after failing prior chemotherapy and/or immunotherapy. Upon physical examination, no significant findings were observed in the axillary regions. We hypothesize that fibroblastic activation may involve sweat glands consequently to systemic therapy, although the reason why the axillary site is favored is not known. Being common in this clinical setting, proper interpretation of this sign is needed.
引用
- Perrone E, Ghai K, Eismant A, et al. Axillary Skin Fibroblast Activation Protein Uptake After Chemo-immunotherapy on PET/CT and SPET/CT: A Mere Coincidence or Causality? Clin Nucl Med. 2025. PMID: 39994903. doi:10.1097/RLU.0000000000005783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。